SCHEMBL4491399

SCHEMBL4491399

Clc1ccc(CN2CCC(CNc3nc4ccccc4[nH]3)CC2)cc1Cl

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.49
GRIN1 Q05586 1/20 0.49
GRIN2B Q13224 1/20 0.49
HTR2B P41595 1/20 0.47
SIGMAR1 Q99720 3/20 0.47
ACHE P22303 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
GFER P55789 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
DCPS Q96C86 1/20 0.46
CCR1 P32246 1/20 0.45
CCR3 P51677 1/20 0.45
TSHR P16473 1/20 0.45
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KCNN1 Q92952 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4501344 0.86 OPRM1 (0.51) OPRM1SIGMAR1ACHEMEN1KMT2A
SCHEMBL4036556 0.85 KCNH2 (0.58) OPRM1HTR2BSIGMAR1GAAMAPT
SCHEMBL4499874 0.84 DCPS (0.45) OPRM1SIGMAR1ACHEMEN1KMT2A
SCHEMBL4503813 0.81 PARP1 (0.54) SIGMAR1MEN1KMT2ACCR3
SCHEMBL4502368 0.79 OPRM1 (0.40) OPRM1SIGMAR1ACHEMAPTMEN1
SCHEMBL4502362 0.77 CACNA1G (0.45) OPRM1SIGMAR1MAPTMEN1KMT2A
SCHEMBL4516525 0.77 TP53 (0.49) OPRM1SIGMAR1MAPTMEN1KMT2A
SCHEMBL12658352 0.76 RAB9A (0.67) GAAGFERMEN1KMT2ASMN1; SMN2
SCHEMBL4503853 0.76 MCHR1 (0.46) GRIN1GRIN2BACHEGAAMAPT
SCHEMBL6325942 0.75 SIGMAR1 (0.46) OPRM1HTR2BSIGMAR1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7517875-B2 Piperidine derivatives having CCR3 antagonism TEIJIN LIMITED (JP) 2009-04-14 US disclosed
US-20070032525-A1 Piperidine derivatives having ccr3 antagonism TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) 2007-02-08 US disclosed
EP-1502916-A1 PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM TEIJIN LIMITED (JP) 2005-02-02 EP disclosed
EP-0857718-B1 ENDOTHELIN ANTAGONIST SUCAMPO AG (CH) 2002-08-14 EP disclosed
EP-0857718-A1 ENDOTHELIN ANTAGONIST R-Tech Ueno, Ltd. (JP) 1998-08-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032525-A1 Piperidine derivatives having ccr3 antagonism CCR3, CCR1, CCR4 OPRM1 388/4885GRIN1 1258/4885GRIN2B 2189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.